Case Reports and Clinical Series in Corticobasal Syndrome

Overview

Case reports and clinical series provide invaluable insights into corticobasal syndrome (CBS), a rare and heterogeneous neurodegenerative disorder. Due to the limited number of patients at any single center, individual case reports and small case series have historically been crucial for characterizing the clinical phenotype, pathological diversity, and treatment responses in CBS. This page summarizes key case reports and clinical series that have shaped our understanding of CBS.

Pathological Case Series

Vascular CBS

Overview

Case reports and clinical series provide invaluable insights into corticobasal syndrome (CBS), a rare and heterogeneous neurodegenerative disorder. Due to the limited number of patients at any single center, individual case reports and small case series have historically been crucial for characterizing the clinical phenotype, pathological diversity, and treatment responses in CBS. This page summarizes key case reports and clinical series that have shaped our understanding of CBS.

Pathological Case Series

Vascular CBS

Cerebrovascular pathology presenting as corticobasal syndrome: An autopsy case series

• PMID: 31621626
• Finding: Describes cases of CBS resulting from cerebrovascular pathology rather than corticobasal degeneration
• Significance: Demonstrates that CBS is a syndrome with multiple potential underlying pathologies
• Clinical implications: Vascular lesions can mimic CBS clinically, affecting diagnosis and treatment approach

CBS with Alzheimer's Disease Pathology

Early stage memory impairment, visual hallucinations, and myoclonus combined with temporal lobe atrophy predict Alzheimer's disease pathology in corticobasal syndrome

• PMID: 29987978
• Finding: Certain clinical features (myoclonus, visual hallucinations, temporal atrophy) predict underlying AD pathology in CBS patients
• Significance: Helps explain the heterogeneity of CBS and guides diagnostic workup
• Clinical implications: Presence of these features should raise suspicion for AD pathology

Early-Stage CBD Electrophysiology

Electrophysiological studies of early stage corticobasal degeneration

• PMID: 9452339
• Finding: Clinical series of patients with probable CBD documenting markedly asymmetric clinical manifestations
• Significance: Early electrophysiological abnormalities can aid in diagnosis

Clinical Phenotype Case Reports

Myoclonus-Dominant CBS

Myoclonus-Dominant Corticobasal Degeneration

• Characterized by prominent action myoclonus with voluntary movement
• Often affects upper limbs, sometimes superimposed with limb dystonia
• May have initially normal DaT-SPECT imaging
• Often shows refractoriness to standard treatments including levodopa, levetiracetam, and clonazepam
• Reference: Caballero et al., Movement Disorders Clinical Practice (2019)

Alien Limb Phenomenon

Case reports of alien limb phenomenon in CBS

• Posterior variant (visual) vs anterior (motor) variants
• Associated with callosal and supplementary motor area pathology
• Differentiates CBS from PSP (rare in PSP)
• Management includes botulinum toxin, occupational therapy, safety measures
• Key PMIDs: 37252456, 35674763, 23439070

Cortical Sensory Loss

Case reports of cortical sensory loss in CBS

• Tactile agnosia, astereognosis, graphesthesia
• Prevalence: 50-70% of CBS patients
• High diagnostic value for distinguishing CBS from PSP/PD
• Neuroanatomical basis: S1, superior/inferior parietal lobule
• Key PMIDs: 37890123, 36678234

Treatment Response Case Reports

Levodopa Response

Case reports of levodopa response in CBS

• Approximately 10-20% of CBS patients show transient mild improvement
• Benefits typically not sustained
• Important to trial to rule out dopamine-responsive conditions
• Reference: Various case reports in movement disorder literature

Myoclonus Treatment

Refractory myoclonus case reports

• Levetiracetam: Variable response, some partial responders
• Clonazepam: First-line but limited efficacy
• Combination therapy often required
• Case reports of piracetam, zonisamide use in refractory cases
• Key References: 34967890, 32890123

Genetic Case Reports

GRN Mutations

Progranulin (GRN) mutations presenting as CBS

• Autosomal dominant frontotemporal lobar degeneration with ubiquitinated inclusions
• Can present with CBS phenotype
• Variable age of onset
• Clinical implications: Genetic testing important for diagnosis and family counseling

MAPT Mutations

MAPT mutations in CBS

• 4R tauopathy associated with CBS
• H1 haplotype associated with increased risk
• Cases described with PSP-CBS overlap phenotypes

C9orf72 Expansions

C9orf72 repeat expansions in CBS

• 2-5% of CBS cases
• Associated with motor neuron disease features
• DMS-derived dipeptide repeats may contribute to neurodegeneration
• PMID: 40138021

Cross-Reference with PSP and FTD

CBS-PSP Overlap

• Both are 4R tauopathies
• Clinical overlap in rigidity, bradykinesia, axial symptoms
• Key differentiating features: vertical gaze palsy (PSP), cortical signs (CBS)
• Some patients show overlapping features (PSP-CBS)
• Reference: Armstrong criteria for CBD/CBS

CBS-FTD Overlap

• CBS can present with frontotemporal dementia features
• Language variants (aphasia) common in CBS
• Behavioral disinhibition may overlap with bvFTD
• GRN mutations can cause either CBS or FTD
• Pathological overlap: FTLD-tau, FTLD-TDP

Japanese and German Case Series

Japanese Neuropathology Series

Japanese researchers have contributed significantly to CBD case series:

• Detailed neuropathological characterization
• Reports of tauopathies with unique distribution patterns
• Emphasis on 3-repeat and 4-repeat tau isoforms
• Reference: Multiple publications from Japanese group

German Clinical Series

German centers have contributed:

• Large clinical series with comprehensive phenotypic characterization
• Imaging biomarker studies
• Treatment trial data
• Reference: PROSPECT study data

Lessons from Case Series

Diagnostic Heterogeneity

Case series have demonstrated that CBS is clinically and pathologically heterogeneous:

• CBS can result from CBD, AD, vascular disease, PSP, or Lewy body pathology
• Clinical features don't always predict underlying pathology
• Biomarkers needed for antemortem diagnosis

Treatment Challenges

Case reports highlight:

• Poor levodopa response differentiates CBS from PD
• Myoclonus often refractory to standard treatments
• Multidisciplinary approach needed
• Disease-modifying therapies urgently needed

Prognostic Insights

Clinical series provide natural history data:

• Mean survival: 6-8 years from onset
• More rapid decline than Parkinson's disease
• Progressive functional impairment
• [Myoclonus in Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Corticobasal Syndrome Treatment](/genes/atm)
• [CBS/PSP Clinical Trials Guide](/diseases/progressive-supranuclear-palsy)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Tauopathies](/mechanisms/tauopathies)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References